Byureon
Novo’s Victoza beats Bydureon in head-to-head trial
March 4, 2011Research and Development, Sales and Marketing Alkermes, Amylin, Byureon, Victoza, diabetes, exenatide, lilly, type II diabetes
Bydureon has been outperformed by rival Victoza in a head-to-trial, decimating shares in its co-developer Amylin and Alkermes, the company …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
